Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530517 · ClinicalTrials.gov registry record · Phase 2
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
A Phase 2 study, sponsored by Zogenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00530517 is a Phase 2 study that has completed, run by Zogenix. The registered enrollment target is 54 participants.
The verdict
NCT00530517, a Phase 2 study, has completed, sponsored by Zogenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment. Study participation will last one month and include 2 doctor visits and 2-4 phone calls.
Interventions
- DEVICE Intraject Sumatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530517
The ClinicalTrials.gov registry entry for NCT00530517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zogenix, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intraject Sumatriptan is the first listed.
NCT00530517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530517 about?
NCT00530517 is a clinical study titled "A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack". Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment. Study participation will last one month and include 2 doctor visits and 2-4 phone calls.
What is the current status of trial NCT00530517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2007-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00530517?
The interventions under investigation include: Intraject Sumatriptan (DEVICE).
Who is sponsoring clinical trial NCT00530517?
This trial is sponsored by Zogenix, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.